L. Fehér

EU-Wide Cross-Sectional Observational Study of Lipid-Modifying Therapy Use in Secondary and Primary Care: the DA VINCI study.

A. Parkhomenko, F. de Leeuw, S. de Servi, 2020, European journal of preventive cardiology.

Clinical characteristics of treatment-resistant depression in adults in Hungary: Real-world evidence from a 7-year-long retrospective data analysis

Z. Rihmer, P. Takacs, P. Kunovszki, 2021, PloS one.

Mortality and the relationship of somatic comorbidities to mortality in schizophrenia. A nationwide matched-cohort study

P. Czobor, I. Bitter, J. Sermon, 2017, European Psychiatry.

Comparative effectiveness of second generation long-acting injectable antipsychotics based on nationwide database research in Hungary

P. Czobor, I. Bitter, J. Sermon, 2019, PloS one.

Comparative effectiveness of depot and oral second generation antipsychotic drugs in schizophrenia: A nationwide study in Hungary

P. Czobor, I. Bitter, P. Takacs, 2013, European Neuropsychopharmacology.

Treatment adherence and insight in schizophrenia.

P. Czobor, I. Bitter, T. Tényi, 2015, Psychiatria Hungarica : A Magyar Pszichiatriai Tarsasag tudomanyos folyoirata.

[Experience with Risperidone in the treatment of institutionalized mentally retarded patients, with special reference to treatment of aggressive states].

L. Fehér, Viktor Hal, 2004, Neuropsychopharmacologia Hungarica.

[Pharmacoeconomic review of the use of injectable long-acting risperidone].

G. Bartkó, L. Fehér, 2005, Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology.